Pictet Asset Management Holding SA Decreases Stock Holdings in Illumina, Inc. $ILMN

Posted by Brenda Bartman on Jul 1st, 2026

Pictet Asset Management Holding SA reduced its position in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) by 12.0% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 266,153 shares of the life sciences company’s stock after selling 36,199 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Illumina were worth $32,306,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Venturi Wealth Management LLC grew its holdings in Illumina by 31.0% in the 1st quarter. Venturi Wealth Management LLC now owns 3,229 shares of the life sciences company’s stock worth $398,000 after acquiring an additional 764 shares during the last quarter. Sicart Associates LLC boosted its holdings in shares of Illumina by 0.7% during the first quarter. Sicart Associates LLC now owns 82,792 shares of the life sciences company’s stock worth $10,205,000 after purchasing an additional 614 shares during the period. Louisiana State Employees Retirement System purchased a new stake in shares of Illumina during the first quarter worth about $5,460,000. RFG Advisory LLC boosted its holdings in shares of Illumina by 6.3% during the first quarter. RFG Advisory LLC now owns 6,547 shares of the life sciences company’s stock worth $807,000 after purchasing an additional 386 shares during the period. Finally, OP Asset Management Ltd bought a new stake in shares of Illumina in the first quarter worth about $1,981,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ILMN. Wall Street Zen downgraded Illumina from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. JPMorgan Chase & Co. upgraded Illumina from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $125.00 to $185.00 in a report on Wednesday, June 10th. Citigroup lifted their price objective on Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a research report on Monday, May 4th. Barclays boosted their target price on Illumina from $122.00 to $145.00 and gave the company an “underweight” rating in a research note on Wednesday, June 24th. Finally, Royal Bank Of Canada assumed coverage on Illumina in a research note on Thursday, May 14th. They issued an “outperform” rating and a $170.00 price target for the company. Eight analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Illumina currently has an average rating of “Hold” and an average target price of $147.18.

Get Our Latest Report on Illumina

Illumina Stock Down 2.9%

ILMN stock opened at $175.83 on Wednesday. The business has a 50 day moving average of $151.42 and a 200 day moving average of $138.36. The firm has a market cap of $26.60 billion, a PE ratio of 31.97, a price-to-earnings-growth ratio of 3.39 and a beta of 1.50. Illumina, Inc. has a twelve month low of $88.00 and a twelve month high of $182.84. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56.

Illumina (NASDAQ:ILMN – Get Free Report) last released its earnings results on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The business had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the previous year, the company posted $0.97 earnings per share. The company’s revenue for the quarter was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, research analysts forecast that Illumina, Inc. will post 5.21 EPS for the current fiscal year.

Insider Transactions at Illumina

In other Illumina news, insider Scott M. Davies sold 615 shares of the firm’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $180.00, for a total transaction of $110,700.00. Following the completion of the sale, the insider directly owned 20,953 shares in the company, valued at approximately $3,771,540. This trade represents a 2.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Leckman sold 783 shares of Illumina stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $162.59, for a total transaction of $127,307.97. Following the completion of the transaction, the senior vice president directly owned 21,259 shares of the company’s stock, valued at $3,456,500.81. This trade represents a 3.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,003,769 shares of company stock worth $155,710,908 over the last quarter. Corporate insiders own 2.90% of the company’s stock.

Illumina Profile

(Free Report)

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.